May Hill Capital LLC Makes New $365,000 Investment in GSK PLC Sponsored ADR (NYSE:GSK)

May Hill Capital LLC acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 9,409 shares of the pharmaceutical company's stock, valued at approximately $365,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Olde Wealth Management LLC acquired a new position in GSK in the 1st quarter worth about $36,000. Lee Danner & Bass Inc. acquired a new position in GSK in the 4th quarter worth about $39,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in GSK in the 4th quarter worth about $40,000. Atala Financial Inc acquired a new position in shares of GSK during the fourth quarter valued at approximately $45,000. Finally, First Pacific Financial acquired a new position in shares of GSK during the first quarter valued at approximately $45,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Up 0.8%

Shares of NYSE GSK traded up $0.30 during mid-day trading on Tuesday, hitting $38.49. The company had a trading volume of 5,121,281 shares, compared to its average volume of 4,935,651. The company has a market capitalization of $78.80 billion, a PE ratio of 19.84, a price-to-earnings-growth ratio of 1.53 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The business's 50-day simple moving average is $39.01 and its 200 day simple moving average is $37.17.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same period last year, the firm earned $0.43 earnings per share. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.38%. GSK's dividend payout ratio (DPR) is currently 87.11%.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of research analyst reports. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. BNP Paribas initiated coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.